“This launch is the first since Lonza’s acquisition of Capsugel and is an important part of our business strategy to drive growth,” said Teun Van der Heide, Head of Capsule Delivery Solutions.
"It will allow our customers to qualify a high-performing, gelling agent-based capsule with the well-known Capsugel high quality and performance standards.”
Stef Vanquickenborne, Head of Research & Development for Lonza’s Capsule Delivery Solutions business, explained: “The new HPMC formulation of Vcaps Gen C meets the demand of pharmaceutical manufacturers for a fast-dissolving, non-animal capsule that is robust and offers a high-performance machinability.”
The Capsugel brand offers several specialty HPMC products, such as Vcaps Plus and Vcaps Enteric.
The addition of Capsugel Vcaps Gen C broadens the already comprehensive HPMC product portfolio, providing solutions for immediate and modified release dosage forms.
This new member of the vegan family will help pharmaceutical customers bring products to market faster, reliably.
